23.5 C
New York
Monday, June 8, 2026

Tag: life sciences

newssourceFORcompanyinformationcontent1marketreleases

Pediatric Relapsed/Refractory Neuroblastoma Market is on an Upward Trend, Driven by Innovation and Unmet Need | DelveInsight

The outlook for the neuroblastoma treatment market is optimistic, fueled by progress in targeted therapies and immunotherapies. GD2-targeted immunotherapy is increasingly being incorporated into...

Pediatric Relapsed/Refractory Neuroblastoma Market is on an Upward Trend, Driven by Innovation and Unmet Need | DelveInsight

The outlook for the neuroblastoma treatment market is optimistic, fueled by progress in targeted therapies and immunotherapies. GD2-targeted immunotherapy is increasingly being incorporated into...

Emmaus Life Sciences Reports Quarterly Financial Results

TORRANCE, Calif., Aug. 14, 2025 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell...

CleanSpace Continues Rapid Growth, Strengthening its Concept-to-Commercialization Model

DOYLESTOWN, Pa., Aug. 14, 2025 /PRNewswire/ -- Continuing its rapid growth, CleanSpace has significantly enhanced its leadership team, expanded its CleanShield service footprint, and...

Made Scientific and New Jersey Delegates Celebrate Grand Opening of Flagship Cell Therapy Manufacturing Facility

New Jersey Department of Labor Commissioner Robert Asaro-Angelo, Assemblywoman Tennille McCoy, Plainsboro Township Mayor Edmund Yates, Middlesex County Board of Commissioners Director Ronald Rios,...

Zifo Launches AI Antibody Engineering App on Snowflake Marketplace to Accelerate Biologics and Drug Discovery

Zifo accelerates antibody engineering and therapeutics development with launch of AI-Powered Protein Models on Snowflake CAMBRIDGE, Mass., CAMBRIDGE, England and CHENNAI, India, Aug. 14,...

Consolidated Interim Report 1 January – 30 June 2025

Consolidated Interim Report 1 January – 30 June 2025
Key points from the H1-2025 report (period 1 January - 30 June 2025)

Clarivate Launches AI-powered Regulatory Assistant Within Cortellis Suite to Boost Productivity and Ease Regulatory Burden

Integrated into Cortellis Regulatory Intelligence, new AI capability helps regulatory teams streamline access to critical intelligence and understand requirements with ease LONDON, Aug. 14, 2025...

AVANT BIO and Portfolio Company Intrepid Labs Earn Nominations for Prestigious Prix Galien USA Awards

AVANT BIO nominated by the prestigious Foundation Galien for the Prix Galien Award in the "Incubators, Accelerators and Equity" category.Unique distinction of having a portfolio...

PureSoftware, a Happiest Minds Company, Secures Two Honors at IBSi Digital Banking Awards 2025 for Arttha’s Excellence in Digital Lending and Wallet Innovation

BENGALURU, India and NAIROBI, Kenya and SINGAPORE, Aug. 13, 2025 /PRNewswire/ -- PureSoftware, a fully owned subsidiary of Happiest Minds, is proud to announce...

Global Digital Health Market Poised for Robust Growth at a CAGR of ~18% by 2032 Amid Rising Demand for Remote Care| DelveInsight

The digital health market is experiencing robust growth, driven by increasing adoption of telemedicine, wearable devices, and AI-powered health solutions. Rising healthcare costs and...

Tumor-Infiltrating Lymphocyte Therapy Market Gains Momentum with Expanding Oncology Applications | DelveInsight

Over the last ten years, cell-based immunotherapy has emerged as a promising approach for treating solid tumors. Several companies, including Iovance Biotherapeutics, Obsidian Therapeutics,...

Tumor-Infiltrating Lymphocyte Therapy Market Gains Momentum with Expanding Oncology Applications | DelveInsight

Over the last ten years, cell-based immunotherapy has emerged as a promising approach for treating solid tumors. Several companies, including Iovance Biotherapeutics, Obsidian Therapeutics,...

vTv Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

•   First study participant randomized in Phase 3 CATT1 trial evaluating cadisegliatin for the treatment of type 1 diabetes with data expected in second half of 2026

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsLife sciences

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers